Candel Therapeutics
February 26, 2024
Oncology
Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage immunotherapy platforms based on novel, genetically modified adenovirus and HSV gene constructs, respectively, and a novel discovery platform called enLIGHTEN™
)
){kind=logo}
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}